Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis
Sponsor: Hospital General Universitario de Alicante
Summary
Acute pancreatitis is a common disease (3rd cause of hospital admission for digestive causes), which is associated with significant patient suffering, a 2-4% probability of death and considerable healthcare costs. Sixty percent of acute pancreatitis are due to the presence of stones in the gallbladder. The risk of suffering another acute biliary pancreatitis (ABP, that is to say, pancreatitis due to gallstones) or of other biliary complications in the following weeks or months is high (20% or greater) if measures are not taken to avoid it, being surgical removal of the gallbladder the most effective. Unfortunately, most Spanish centers have a surgical waiting list that makes gallbladder surgery unfeasible in a period of less than weeks or months, which is why readmission for biliary problems derived from the stones is a common problem. This, of course, causes danger and great stress and anger for patients affected by these complications on the waiting list, damaging their relationship with the health system and it is linked to increased cost. In addition, there is a very vulnerable group, those patients who due to age or serious diseases cannot undergo gallbladder surgery but have a high probability of suffering biliary problems due to the stones they have. Ursodeoxycholic acid (UDCA) is very safe drug which is used to dissolve gallstones, but its role in preventing biliary complications after ABP has not been studied adequately so it is not frequently used. Our objective is to investigate if UDCA is useful in this scenario, which would avoid suffering and adverse consequences for the patient and reduce the consumption of resources.
Official title: Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis, a Double-blind Multicenter Randomized-controlled Trial. OSOPOLAR Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
332
Start Date
2021-11-10
Completion Date
2027-07-01
Last Updated
2025-03-20
Healthy Volunteers
No
Conditions
Interventions
Ursodeoxycholic Acid
Ursodeoxycholic Acid will be administered to patients in the UDCA group as a prophylactic measure of future complications associated to gallstones
Placebo
Placebo: composition per 100g: colloidal silica 1.95g and cellulose microcrystalline 98.05g.
Locations (18)
Hospital Clínico Universitario de Santiago
Santiago de Compostela, A coruña, Spain
Hospital General Universitario de Alicante
Alicante, Alicante, Spain
Hospital General Universitario de Elche
Elche, Alicante, Spain
Hospital Univerisitario Vall D´Hebron
Barcelona, Barcelona, Spain
Hospital de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Consorci Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Clínio San Cecilio
Granada, Granada, Spain
Hospital Ramon y Cajal
Madrid, Madrid, Spain
Hospital Costa del Sol,
Marbella, Málaga, Spain
Clinica Unversidad de Navarra
Pamplona, Navarre, Spain
Complejo Hospitalario de Ourense
Ourense, Ourense, Spain
Hospital Universitario Central de Asturias.
Oviedo, Principality of Asturias, Spain
Hospital Clínico Universitario de Valencia
Alicante, Valencia, Spain
Hospital Clínico Universitario de Valladolid
Valladolid, Valladolid, Spain
Hospital Universitario de Cruces
Bilbao, Vizcaya, Spain
Hospital Clínico Lozano Blesa
Zaragoza, Zaragoza, Spain
Hospital Universitario Miguel Servet
Zaragoza, Zaragoza, Spain